ISV-403

· Bausch & Lomb Incorporated

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ISV-403, covering 2012-08-13 to 2012-08-13. Get the full timeline:

Most recent: Clinical Trial Update: Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days [Phase 1]